FindTrial
Sign In

Comparison of ursodeoxycholic acid 900 mg/day and 1200 mg/day for chronic hepatitis C patients

Comparison of ursodeoxycholic acid 900 mg/day and 1200 mg/day for chronic hepatitis C patients - Comparison of UDCA 900 mg/day and 1200 mg/day for chronic hepatitis C

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001471
Enrollment
40
Registered
2008-12-01
Start date
2008-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

UDCA 900 mg/day UDCA 1200 mg/day

Sponsors

Department of Gastroenterology, the University of Tokyo Hospital
Lead Sponsor
Department of Oncology, Chiba University Department of Gastroenterology and Hepatology, Nihon University
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: positive for HCV-RNA serum ALT >= 61 IU/L

Exclusion criteria

Exclusion criteria: decompensated cirrhosis under anti-viral therapy complete biliary obstruction pregnancy

Design outcomes

Primary

MeasureTime frame
decrease in serum ALT levels—

Secondary

MeasureTime frame
adverse events—

Countries

Japan

Contacts

Public ContactHaruhiko YOSHIDA

The University of Tokyo Gastroenterology

yoshida-2im@h.u-tokyo.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026